Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Authors:
- on behalf of the ACTIVATE Study GroupOGon behalf of the ACTIVATE Study Group
- Evan B. CunninghamECEvan B. Cunningham
- Behzad HajarizadehBHBehzad Hajarizadeh
- Olav DalgardODOlav Dalgard
- Janaki AminJAJanaki Amin
- Margaret HellardMHMargaret Hellard
- Graham R FosterGFGraham R Foster
- Philip BruggmannPBPhilip Bruggmann
- Brian ConwayBCBrian Conway
- Markus BackmundMBMarkus Backmund
- Geert RobaeysGRGeert Robaeys
- Tracy SwanTSTracy Swan
Open Access
- 13 June 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-12
Abstract
The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin for 12 (undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4). Outcomes included treatment completion, PEG-IFN adherence, ribavirin adherence, and sustained virological response (SVR, undetectable HCV RNA >12 weeks post-treatment). Among 93 people treated, 59% had recently injected drugs (past month), 77% were receiving OST and 56% injected drugs during therapy. Overall, 76% completed treatment. Mean on-treatment adherence to PEG-IFN and ribavirin were 98.2% and 94.6%. Overall, 6% of participants missed >1 dose of PEG-IFN and 31% took <95% of their prescribed ribavirin., Higher treatment completion was observed among those receiving 12 vs. 24 weeks of treatment (97% vs. 46%, P < 0.001) while the proportion of participants with 95% on-treatment ribavirin adherence was similar between groups (67% vs. 72%, P = 0.664). Receiving 12 weeks of therapy was independently associated with treatment completion. No factors were associated with 95% RBV adherence. Neither recent injecting drug use at baseline nor during therapy was associated with treatment completion or adherence to ribavirin. In adjusted analysis, treatment completion was associated with SVR (aOR 23.9, 95% CI 2.9–193.8). This study demonstrated a high adherence to directly observed PEG-IFN and self-administered ribavirin among people with ongoing injecting drug use or receiving OST. These data also suggest that shortening therapy from 24 to 12 weeks can lead to improved treatment completion. Treatment completion was associated with improved response to therapy. ACTIVATE trial registration number: NCT01364090 - May 31, 2011Keywords
Funding Information
- Merck (IISP38463)
This publication has 25 references indexed in Scilit:
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug usersJournal of Hepatology, 2011
- Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational studyLiver International, 2011
- Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapyAddiction, 2010
- Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis CLiver International, 2010
- Review article: adherence to medication for chronic hepatitis C – building on the model of human immunodeficiency virus antiretroviral adherence researchAlimentary Pharmacology & Therapeutics, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Community‐based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug useAlimentary Pharmacology & Therapeutics, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008